Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
Pauline Byakika-Kibwika1,2, Mohammed Lamorde1,2, Harriet Mayanja-Kizza1, Concepta Merry1,2, Bob Colebunders3,4, Jean-Pierre Van geertruyden4,5
1Infectious Diseases Institute and Infectious Diseases Network for Treatment and Research in Africa (INTERACT), Faculty of Medicine, Makerere University, Kampala Uganda; 2Trinity College Dublin, Ireland; 3Dienst Clinical Sciences, Instituut voor Tropische Geneeskunde, Antwerp, Belgium; 4International Health, Epidemiology en Social Medicine, Universiteit Antwerpen, Antwerp, Belgium; 5Epidemiology Unit, Dienst Parasitologie, Instituut voor Tropische Geneeskunde, Antwerp, Belgium
Abstract: Artemether–lumefantrine is one of the artemisisnin-based combination therapies recommended for treatment of uncomplicated falciparum malaria. The drug combination is highly efficacious against sensitive and multidrug resistant falciparum malaria. It offers the advantage of rapid clearance of parasites by artemether and the slower elimination of residual parasites by lumefantrine. The combination can be used in all populations except pregnant mothers in the first trimester where safety is still uncertain. There are still concerns about safety and pharmacokinetics of the drug combination in children, especially infants, pregnant mothers and drug interactions with mainly non-nucleoside reverse transcriptase inhibitors and protease inhibitors used for HIV therapy.
Keywords: artemether–lumefantrine, efficacy, effectiveness, safety, malaria
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]